NCT01722812已完成2 期
An Exploratory Study Evaluating the Efficacy of Cromoglicate Cream Compared to Cream Vehicle in the Treatment of Itch in Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Evaluation of change in visual analogue scale
研究概览
简要总结
The purpose of this exploratory study is to investigate the clinical efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent has been obtained
- •Age 18 years or above
- •Either sex
- •Any race or ethnicity
- •Attending hospital outpatient clinic or the private practice of a dermatologist
- •Clinical diagnosis of stable plaque psoriasis of at least 6 months with a symmetric distribution
- •Two treatment areas with a symmetrical distribution each corresponding to 2-3% BSA (Body Surface Area) and each including at least one itchy psoriasis plaque
- •Itchy psoriasis on both intended treatment areas of at least 40mm on the Visual Analogue Scale (VAS) with a maximum difference of 10mm on the visual analogue scale between each of the two treatment areas
- •Disease severity graded mild, moderate or severe according to the Physician's global assessment (PGA) of disease severity on psoriasis plaques on each of the two treatment areas. The disease severity must be the same for both treatment areas
排除标准
- •Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
- •etanercept - within 4 weeks prior to randomisation
- •adalimumab, infliximab - within 8 weeks prior to randomisation
- •ustekinumab - within 16 weeks prior to randomisation
- •other products - 4 weeks/5 half-lives (whichever is longer)
- •Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin, fumaric acid derivatives, and other immunosuppressants) within 4 weeks prior to randomization
- •Any topical treatment of the treatment areas (except for emollients) within 2 weeks prior to randomisation.
- •Treatment with therapies, whether marketed or not, with a possible effect on itch within the following time periods prior to randomisation:
- •antihistamines - within 1 week prior to randomisation
- •gabapentin - within 4 weeks prior to randomisation
- •Subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation or longer, if the class of substance required a longer treatment free period as defined in exclusion criterion 1 for biological treatments
- •PUVA (Psoralen and Ultraviolet A Radiation) or Grenz ray therapy within 4 weeks prior to randomisation.
- •UVB therapy within 2 weeks prior to randomisation
- •Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) within 2 weeks prior to randomisation
- •Subjects with current participation in any other interventional clinical trial
- •Subjects with any of the following conditions present on the treatment areas: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, icthyosis, ulcers and wounds
- •Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis) on the treatment area that may confound the evaluation of psoriasis
- •Subjects with a history of serious allergy, allergic skin rash or sensitivity to any component of the investigational products or formulations being tested
- •Known or suspected severe renal insufficiency or severe hepatic disorders
- •Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
- •Planned exposure to the sun during the study that may affect psoriasis vulgaris (i.e., normal lifestyle outdoor activities are permitted but deliberate exposure to sunlight or artificial ultraviolet light should be avoided)
- •Subjects previously randomised into this trial
- •Not all of the exclusion criteria listed due to limited space
研究组 & 干预措施
Placebo (left) / Cromoglicate (right)
Other
Placebo (on a lesion on left body side), Cromoglicate (on a lesion on right body side)
干预措施: Placebo (Drug)
Placebo (right) / Cromoglicate (left)
Other
Placebo (on a lesion on right body side), Cromoglicate (on a lesion on left body side)
干预措施: Cromoglicate (Drug)
结局指标
主要结局
Evaluation of change in visual analogue scale
时间窗: Baseline to week 2
次要结局
- Evaluation of change in 4-point itch scale, 7-point itch scale, duration of itch and comparison of treated areas(Baseline to week 2)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical and Biological Anti-aging Efficacy of a Cosmetic CreamAnti-agingNCT05895591Pierre Fabre Dermo Cosmetique33
已完成
4 期
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque PsoriasisPsoriasisNCT01714544Promius Pharma, LLC60
招募中
3 期
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisAcne VulgarisNCT06403501Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.692
已完成
不适用
Clinical Study for the Evaluation of P-3075 Cream on Acne TreatmentAcneNCT01948570Derming SRL40
招募中
2 期
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical TrialDementia With Lewy BodiesNCT04588285Helse Fonna180